[
  {
    "ts": null,
    "headline": "Encompass Health (EHC) Q2 Earnings and Revenues Surpass Estimates",
    "summary": "Encompass Health (EHC) delivered earnings and revenue surprises of +16.67% and +2.29%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?",
    "url": "https://finnhub.io/api/news?id=a567bb3d81c6afa212ae3a119836b0a77474cb313a95d06859d59b967e01b6b0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754343302,
      "headline": "Encompass Health (EHC) Q2 Earnings and Revenues Surpass Estimates",
      "id": 136206255,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DVA",
      "source": "Yahoo",
      "summary": "Encompass Health (EHC) delivered earnings and revenue surprises of +16.67% and +2.29%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?",
      "url": "https://finnhub.io/api/news?id=a567bb3d81c6afa212ae3a119836b0a77474cb313a95d06859d59b967e01b6b0"
    }
  },
  {
    "ts": null,
    "headline": "Akebia Initiates Vafseo® (vadadustat) Post-Marketing Study in Conjunction with Large Dialysis Organization",
    "summary": "VOCAL, an open-label active-controlled study, is being conducted at DaVita dialysis clinics to evaluate benefits of treating patients with Vafseo three times a weekCAMBRIDGE, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the initiation of a post-marketing study to identify additional potential benefits of Vafseo® (vadadustat). The VOCAL tria",
    "url": "https://finnhub.io/api/news?id=396dfde337396b39c6234ae82b3bc1fe8b3d801f6cb385bf9f2ce7273c898fc0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754308800,
      "headline": "Akebia Initiates Vafseo® (vadadustat) Post-Marketing Study in Conjunction with Large Dialysis Organization",
      "id": 136198404,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DVA",
      "source": "Yahoo",
      "summary": "VOCAL, an open-label active-controlled study, is being conducted at DaVita dialysis clinics to evaluate benefits of treating patients with Vafseo three times a weekCAMBRIDGE, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the initiation of a post-marketing study to identify additional potential benefits of Vafseo® (vadadustat). The VOCAL tria",
      "url": "https://finnhub.io/api/news?id=396dfde337396b39c6234ae82b3bc1fe8b3d801f6cb385bf9f2ce7273c898fc0"
    }
  },
  {
    "ts": null,
    "headline": "DaVita (DVA) To Report Earnings Tomorrow: Here Is What To Expect",
    "summary": "Dialysis provider DaVita Inc. (NYSE:DVA) will be reporting results this Tuesday after market hours. Here’s what to look for.",
    "url": "https://finnhub.io/api/news?id=a187bd3b029696c37228ac6e23a02c473f688495348d638eff05ce75093ee976",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754276702,
      "headline": "DaVita (DVA) To Report Earnings Tomorrow: Here Is What To Expect",
      "id": 136198405,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DVA",
      "source": "Yahoo",
      "summary": "Dialysis provider DaVita Inc. (NYSE:DVA) will be reporting results this Tuesday after market hours. Here’s what to look for.",
      "url": "https://finnhub.io/api/news?id=a187bd3b029696c37228ac6e23a02c473f688495348d638eff05ce75093ee976"
    }
  }
]